



Gallopamil

Pharmacological and Clinical Profile
of a Calcium Antagonist

Edited by
M. Kaltenbach and R. Hopf

With Contributions by
M. Bakos V. Bühler Y. K. Byon F. Custović E. Dora H. Drews
A. Fleckenstein B. Fleckenstein G. Fleckenstein-Grün J. Gries
H. G. Hege J. Hescheler M. Hollmann R. Hopf R. Ivančić
H. Jahrmärker M. Kaltenbach A. Koller A. G. B. Kovách
L. Ligeti R. Maurer I. Mitrovíc V. Mitrovíc H. Nawrath
H. Neuss L. Niemelä M. Raschack G. Rettig G. Rubányi
E. Sauer J. Schiemann M. Schlepper H. Sebening S. Sen
M. Sesto F. Späh B. Stieren M. Sučić F. Theisen W. Trautwein
J. Weymann Xian-Gang Zong

Translated by T. L. Janson

With 108 Figures

Springer-Verlag Berlin Heidelberg GmbH 1984

Professor Dr. med. Martin Kaltenbach
Priv.-Doz. Dr. med. Rüdiger Hopf

Department of Cardiology
Centre for Internal Medicine
University Clinical Centre
Theodor-Stern-Kai 7
D-6000 Frankfurt/Main 70
Federal Republic of Germany

Translator: T. L. Janson, Janson Translations Ltd.
Janson House, 12 Albert Street, Fleet,
Hampshire GU13 9RL, Great Britain

Title of the original German edition: Gallopamil
Springer-Verlag Berlin Heidelberg 1983

ISBN 978-3-540-13737-5 ISBN 978-3-662-07364-3 (eBook)
DOI 10.1007/978-3-662-07364-3

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use, a fee is payable to "Verwertungsgesellschaft Wort", Munich.

© by Springer-Verlag Berlin Heidelberg 1984
Originally published by Springer-Verlag Berlin Heidelberg New York in 1984.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Typesetting : G. Appl, Wemding.
2121/3140-543 210

Preface

Since the introduction of Gallopamil in 1983 this drug has been applied in similar indications as Verapamil. Predominantly patients with stable or unstable angina pectoris, with hypertension, and hypertrophic cardiomyopathy have been treated.

As far as can be judged from preliminary clinical experience Gallopamil achieves similar results as Verapamil with much lower doses. Instead of 3 times 160 mg Verapamil 2 to 3 times 50 mg Gallopamil can be applied.

Although the spectrum of side effects of both drugs is similar it is evident that occasionally patients can tolerate one better than the other. Complaints about constipation may be less frequent with Gallopamil whereas stomach trouble may be more frequent.

Frankfurt, August 1984

M. KALTENBACH
R. HOPF

Table of Contents

Gallopamil (D 600) – a Calcium Antagonist of High Potency and Specificity. Effects on the Myocardium and Pacemakers (A. FLECKENSTEIN, B. FLECKENSTEIN, F. SPÄH and Y. K. BYON)	1
Blockade of the Ca ²⁺ -dependent Bioelectrical Automaticity and Electromechanical Coupling of Smooth Muscle Cells by Gallopamil (D 600) (G. FLECKENSTEIN-GRÜN and A. FLECKENSTEIN)	33
Studies on the Mechanism of Action of D 600 on Isolated Myocytes (W. TRAUTWEIN and J. HESCHELER)	49
Studies In Vitro and In Vivo on the Effect of Gallopamil on Coronary Vessels (A. G. B. KOVÁCH, L. LIGETI, M. BAKOS, G. RUBÁNYI and A. KOLLER)	58
Electrophysiological Studies with Gallopamil on the Myocardium of the Human Ventricle (H. NAWRATH and XIAN-GANG ZONG)	66
Studies on the Cardiovascular Effects of Gallopamil (M. RASCHACK, J. GRIES, V. BÜHLER and R. MAURER)	72
Antihypoxic Effect of Gallopamil in the Brain (A. G. B. KOVÁCH, E. DORA and A. KOLLER)	81
Pharmacokinetics and Metabolism of Gallopamil (B. STIEREN, V. BÜHLER, H. G. HEGE, M. HOLLMANN, H. NEUSS, M. SCHLEPPER and J. WEYMANN)	88
The Effect of Gallopamil on the Haemodynamics of Patients with Coronary Heart Disease (M. SESTO, R. IVANČIĆ and F. CUSTOVIĆ)	94
Pharmacodynamics and Electrophysiology of Gallopamil (H. NEUSS, V. MITROVIĆ, I. MITROVIĆ, B. STIEREN, V. BÜHLER and M. SCHLEPPER)	99
Anti-anginal Effect of the Calcium Antagonist Gallopamil (V. MITROVIĆ, L. NIEMELÄ, H. NEUSS and M. SCHLEPPER)	107

Effect of Gallopamil on Coronary Arteries and Haemodynamics (H. SEBENING and E. SAUER)	114
Effect of Gallopamil (D 600) on the ECG During Exercise, in Coronary Heart Disease (F. THEISEN and H. JAHRMÄRKER)	117
Anti-anginal Effect of Gallopamil as Compared with Nifedipine (R. HOPF, H. DREWS and M. KALTENBACH)	123
Results of an Open Multicentre Study with 455 Patients with Coronary Heart Disease, Treated with Gallopamil for 1 Year (M. SUČIĆ and J. SCHIEMANN)	132
Acute and Long-term Effects of Gallopamil in Patients with Stable Angina Pectoris (G. RETTIG and S. SEN)	136

List of Contributors

M. BAKOS

Exper. Research Dept. and 2nd Inst. of Physiology, Semmelweis University Medical School, Budapest, Hungary

V. BÜHLER

BASF Aktiengesellschaft, Operating Division Pharmaceuticals, Research and Development, Knoll AG, Postfach 21 08 05, 6700 Ludwigshafen, Federal Republic of Germany

Y. K. BYON

Institute of Physiology, University of Freiburg, Hermann-Herder-Straße 7, 7800 Freiburg, Federal Republic of Germany

F. CUSTOVIĆ

Institut Za Bolesti Srca i Klinicki Bolnicki, Centar Rebro, 41000 Zagreb, Yugoslavia

E. DORA

Exper. Research Dept. and 2nd Inst. of Physiology, Semmelweis University Medical School, Budapest, Hungary

H. DREWS

Department of Cardiology, Centre for Internal Medicine, Clinical Centre of the Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, D-6000 Frankfurt/Main 70, Federal Republic of Germany

A. FLECKENSTEIN

Institute of Physiology, University of Freiburg, Hermann-Herder-Straße 7, 7800 Freiburg, Federal Republic of Germany

B. FLECKENSTEIN

Institute of Physiology, University of Freiburg, Hermann-Herder-Straße 7, 7800 Freiburg, Federal Republic of Germany

G. FLECKENSTEIN-GRÜN

Institute of Physiology, University of Freiburg, Hermann-Herder-Straße 7, 7800 Freiburg, Federal Republic of Germany

J. GRIES

BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 21 08 05,
6700 Ludwigshafen, Federal Republic of Germany

H. G. HEGE

BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 21 08 05,
6700 Ludwigshafen, Federal Republic of Germany

J. HESCHELER

2nd Institute of Physiology, University of the Saar,
6650 Homburg/Saar, Federal Republic of Germany

M. HOLLMANN

BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 21 08 05,
6700 Ludwigshafen, Federal Republic of Germany

R. HOPF

Department of Cardiology, Centre for Internal Medicine,
Clinical Centre of the Johann Wolfgang Goethe University,
Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Federal
Republic of Germany

R. IVANČIĆ

Institut Za Bolesti Srca i Klinicki Bolnicki, Centar Rebro,
41000 Zagreb, Yugoslavia

H. JAHRMÄRKER

Innenstadt Medical Department, University of Munich,
Ziemssenstraße 1, 8000 München 2, Federal Republic of
Germany

M. KALTENBACH

Department of Cardiology, Centre for Internal Medicine,
Clinical Centre of the Johann Wolfgang Goethe University,
Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Federal
Republic of Germany

A. KOLLER

Exper. Research Dept. and 2nd Inst. of Physiology, Semmelweis
University Medical School, Budapest, Hungary

A. G. B. KOVÁCH

Exper. Research Dept. and 2nd Inst. of Physiology, Semmelweis
University Medical School, Budapest, Hungary

L. LIGETI

Exper. Research Dept. and 2nd Inst. of Physiology, Semmelweis
University Medical School, Budapest, Hungary

X

R. MAURER
BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 210805,
6700 Ludwigshafen, Federal Republic of Germany

I. MITROVIĆ
Wilhelm-Kerckhoff Hospital, Benekestraße 4–6, 6350 Bad
Nauheim, Federal Republic of Germany

V. MITROVIĆ
Wilhelm-Kerckhoff Hospital, Benekestraße 4–6, 6350 Bad
Nauheim, Federal Republic of Germany

H. NAWRATH
Institute of Pharmacology, University of Mainz, Obere
Zahlbacherstraße 67, 6500 Mainz, Federal Republic of Germany

H. NEUSS
Wilhelm-Kerckhoff Hospital, Benekestraße 4–6, 6350 Bad
Nauheim, Federal Republic of Germany

L. NIEMELÄ
Wilhelm-Kerckhoff Hospital, Benekestraße 4–6, 6350 Bad
Nauheim, Federal Republic of Germany

M. RASCHACK
BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 210805,
6700 Ludwigshafen, Federal Republic of Germany

G. RETTIG
Internal Medicine III, University Hospital and Outpatient
Department, 6650 Homburg/Saar, Federal Republic of
Germany

G. RUBÁNYI
Exper. Research Dept. and 2nd Inst. of Physiology, Semmelweis
University Medical School, Budapest, Hungary

E. SAUER
Landshut-Achdorf District Hospital, 8300 Landshut, Federal
Republic of Germany

J. SCHIEMANN
BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 210805,
6700 Ludwigshafen, Federal Republic of Germany

M. SCHLEPPER
Wilhelm-Kerckhoff Hospital, Benekestraße 4–6, 6350 Bad
Nauheim, Federal Republic of Germany

H. SEBENING

1st Medical Department, Technical University, Ismaninger
Straße 22, 8000 München 80, Federal Republic of Germany

S. SEN

Internal Medicine III, University Hospital and Outpatient
Department, 6650 Homburg/Saar, Federal Republic of
Germany

M. SESTO

Institut Za Bolesti Srca i Klinicki Bolnicki, Centar Rebro,
41000 Zagreb, Yugoslavia

F. SPÄH

Institute of Physiology, University of Freiburg,
Hermann-Herder-Straße 7, 7800 Freiburg, Federal Republic of
Germany

B. STIEREN

BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 210805,
6700 Ludwigshafen, Federal Republic of Germany

M. SUČIĆ

BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 210805,
6700 Ludwigshafen, Federal Republic of Germany

F. THEISEN

Innenstadt Medical Department, University of Munich,
Ziemssenstraße 1, 8000 München 2, Federal Republic of
Germany

W. TRAUTWEIN

2nd Institute of Physiology, University of the Saar, 6650
Homburg/Saar, Federal Republic of Germany

J. WEYMANN

BASF Aktiengesellschaft, Operating Division Pharmaceuticals,
Research and Development, Knoll AG, Postfach 210805,
6700 Ludwigshafen, Federal Republic of Germany

XIAN-GANG ZONG

Institute of Pharmacology, University of Mainz, Obere
Zahlbacherstraße 67, 6500 Mainz, Federal Republic of Germany